18 December 2025 - Knight Therapeutics announced today that Health Canada has approved Wynzora, a white uniform cream containing 0.05 mg/g of calcipotriol and 0.5 mg/g of betamethasone dipropionate, indicated for the topical treatment of psoriasis vulgaris in adults and adolescents aged 12-17 years for up to 8 weeks.

Knight obtained the Canadian rights to Wynzora through its June 2025 acquisition of the assets of Paladin Pharma.

Read Knight Therapeutics press release